Intermittent (oral) Rybelsus / Semaglutide use in healthy individuals?

#508

Good news on the GLP1 front:

  • Some analysts say Eli Lilly’s daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors.
  • In the trial, orforglipron caused weight loss that missed Wall Street’s expectations and came below what Novo Nordisk reported for its oral drug in a separate study.
  • But Eli Lilly’s drug could have a few advantages over Novo Nordisk’s pill, including a lack of dietary restrictions, easier manufacturing and a potentially lower price, according to some analysts.
4 Likes
#509

I do think it could end up being extremely popular, depending on tolerability and cost/access, since so many people prefer pills to injections and being able to take it with food is a big bonus.

It also might have a place for long-term maintenance (lose weight fast with retatrutide, for instance, then switch to orfo to keep it off). Also for those who want a less aggressive therapy to lose 10 or 15 pounds of fat to look better and be healthier.

5 Likes